compounded semaglutide enforcement news injections will no longer be sold at compounding pharmacies after May 22 FDA and Novo Nordisk Warned

Do not administer more than 1 tablet per day

Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP-1s [71]

While GLP-1 agonists work well for controlling blood sugar and helping with weight loss, its important to remember that they arent suitable for everyone, including pregnant individuals or those with certain pre-existing health conditions, like a history of pancreatitis

Other factors matter, including: Retatrutide may become an important future treatment if it is approved, but Mounjaro is the current licensed option

[7] [8] GIP receptor activation may further support insulin sensitivity and fat metabolism, whilst glucagon receptor agonism is hypothesised to promote energy expenditure and reduce hepatic fat accumulation

Oral semaglutide (Wegovy pill, Rybelsus) should not be taken while breastfeeding because it contains an absorption enhancer thats known to pass into breast milk